Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab and Sacituzumab Govitecan in SCLC and EP-NEC
NCT07328490Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab, sacituzumab govitecan in small cell lung cancer (SCLC), neuroendocrine cancer, sponsored by National Cancer Institute. Planned start Apr 2026; status: withdrawn.
02
Drugs
tarlatamabsacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)neuroendocrine cancer
Beyond the preview
Go deeper on NCT07328490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328490.